Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters

Database
Language
Journal subject
Publication year range
1.
Ann Oncol ; 35(5): 458-472, 2024 May.
Article in English | MEDLINE | ID: mdl-38417742

ABSTRACT

BACKGROUND: Although germline BRCA mutations have been associated with adverse outcomes in prostate cancer (PC), understanding of the association between somatic/germline alterations in homologous recombination repair (HRR) genes and treatment outcomes in metastatic castration-resistant PC (mCRPC) is limited. The aim of this study was to investigate the prevalence and outcomes associated with somatic/germline HRR alterations, particularly BRCA1/2, in patients initiating first-line (1L) mCRPC treatment with androgen receptor signalling inhibitors (ARSi) or taxanes. PATIENTS AND METHODS: Data from 729 mCRPC patients were pooled for CAPTURE from four multicentre observational studies. Eligibility required 1L treatment with ARSi or taxanes, adequate tumour samples and biomarker panel results. Patients underwent paired normal and tumour DNA analyses by next-generation sequencing using a custom gene panel including ATM, BRCA1, BRCA2, BRIP1, CDK12, CHEK2, FANCA, HDAC2, PALB2, RAD51B and RAD54L. Patients were divided into subgroups based on somatic/germline alteration(s): with BRCA1/2 mutations (BRCA); with HRR mutations except BRCA1/2 (HRR non-BRCA); and without HRR alterations (non-HRR). Patients without BRCA1/2 mutations were classified as non-BRCA. Radiographic progression-free survival (rPFS), progression-free survival 2 (PFS2) and overall survival (OS) were assessed. RESULTS: Of 729 patients, 96 (13.2%), 127 (17.4%) and 506 (69.4%) were in the BRCA, HRR non-BRCA and non-HRR subgroups, respectively. BRCA patients performed significantly worse for all outcomes than non-HRR or non-BRCA patients (P < 0.05), while PFS2 and OS were significantly shorter for BRCA than HRR non-BRCA patients (P < 0.05). HRR non-BRCA patients also had significantly worse rPFS, PFS2 and OS than non-HRR patients. Exploratory analyses suggested that for BRCA patients, there were no significant differences in outcomes associated with 1L treatment choice (ARSi or taxanes) or with the somatic/germline origin of the alterations. CONCLUSIONS: Worse outcomes were observed for mCRPC patients in the BRCA subgroup compared with non-BRCA subgroups, either HRR non-BRCA or non-HRR. Despite its heterogeneity, the HRR non-BRCA subgroup presented worse outcomes than the non-HRR subgroup. Screening early for HRR mutations, especially BRCA1/2, is crucial in improving mCRPC patient prognosis.


Subject(s)
Germ-Line Mutation , Prostatic Neoplasms, Castration-Resistant , Recombinational DNA Repair , Humans , Male , Prostatic Neoplasms, Castration-Resistant/genetics , Prostatic Neoplasms, Castration-Resistant/drug therapy , Prostatic Neoplasms, Castration-Resistant/pathology , Prostatic Neoplasms, Castration-Resistant/mortality , Aged , Recombinational DNA Repair/genetics , Middle Aged , BRCA2 Protein/genetics , Aged, 80 and over , Taxoids/therapeutic use , BRCA1 Protein/genetics , Androgen Receptor Antagonists/therapeutic use , Biomarkers, Tumor/genetics , Progression-Free Survival , Mutation
2.
Article in English | MEDLINE | ID: mdl-24110018

ABSTRACT

Numerous improved physics-based methods for Linac photon spectra reconstruction have been published; some of them are based on transmission data analysis and others on scattering data. In this work, the two spectrum unfolding approaches are compared in order to experimentally validate its robustness and to determine which is the optimal methodology for application on a clinical quality assurance routine. Both studied methods are based on EPID images generated when the incident photon beam impinges onto plastic blocks. The distribution of transmitted/scatter radiation produced by this object centered at the beam field size was measured. Measurements were performed using a 6 MeV photon beam produced by the linear accelerator. The same radiation distribution conditions were also simulated with Monte Carlo code for a series of monoenergetic identical geometry photon beams for both cases. Two systems of linear equations were generated to combine the polyenergetic EPID measurements with the monoenergetic simulation results. Regularization techniques were applied to solve the systems for obtaining the incident photon spectrum. We present a comparison between the well-known photon Spectral Reconstruction based on Transmission Data (Trans-based) technology and the Spectral Reconstruction based on Scattering Data (Scatt-based), which we both developed using EPID images. It is shown that Trans-based reconstruction results display much better agreement with photon spectrum theoretical predictions.


Subject(s)
Radiotherapy, Intensity-Modulated , Algorithms , Image Processing, Computer-Assisted , Monte Carlo Method , Particle Accelerators , Photons , Scattering, Radiation , Silicon/chemistry
SELECTION OF CITATIONS
SEARCH DETAIL